Immunologische Analysen zur Studie „A randomized phase Ib study of biological activity, safety, tolerability and clinical activity of different dose levels of EMD 640744 in Montanide® ISA 51 administered in subjects with advanced solid tumors“ (EMR 200 032-001)
Laufzeit: 01.01.2007 - 31.12.2009